constipation
Conditions
Interventions
Placebo group:Placebo
Bifidobacterium longum CCFM1112 group:1 billion Bifidobacterium longum CCFM1112
Lactobacillus rhamnosus CCFM1069 group:1 billion Lactobacillus rhamnosus CCFM1069
Sponsors
The Second People's Hospital in Wuxi
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. There is no restriction on gender and race, aged 18-65 years old; 2. Must meet Rome IV standard; (1) Meet at least 2 or more of the following criteria: 1) Difficulty defecation or sensation of defecation (more than 25% of the time); 2) Drain the ball pits or hard pits (more than 25%) (Bristol Thermal Character Scale 1-2); 3) A sense of not being exhausted (more than 25% of the time); 4) Anorectal obstruction or blockage (more than 25% of the time); 5) Need artificial help to defecate (such as finger defecation, support pelvic floor) (more than 25% of the time); 6) Spontaneous bowel movements 3 times a week; (2) Loose stools without laxatives; (3) Only the diagnosis of IBS is classic; (4) Symptoms appeared >= 6 months before diagnosis, and the above diagnostic criteria appeared in the past 3 months; 3. Did not use any drugs that affect gastrointestinal motility in the past week; 4. Good compliance, able to adhere to the regulations according to the requirements of clinical trials; 5. The informed or consenting person has agreed to the consent form; 6. Respond to the signal to notify the consent form, basic situation survey form, parallel structure and living conditions survey, and promise to cooperate with the research during the entire trial period.
Exclusion criteria
Exclusion criteria: 1. Constipation caused by other diseases, functional defecation disorders and drugs, such as: Parkinson's syndrome, prerectal pelvic spasm, Hirschsprung's disease, hypothyroidism, and long-term use of pain medications; 2. Those who cannot follow the observation due to alcoholism, drug abuse or mental factors; 3. Long-term abuse of laxatives; 4. Short-term (1 week) or long-term use of antibiotics; 5. Allergy or intolerance to the ingredients of the tested probiotic products; 6. Women who are pregnant or breastfeeding, or women who plan to become pregnant or breastfeeding during the study period; 7. Subjects considered by the researcher to be unsuitable for inclusion in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal flora;Fecal flora genomics;Blood routine;Urine routine;Fecal routine;All Blood Cells Analysis;Serum IgE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Height;Weight;liver function;Blood lipid level; | — |
Countries
China
Contacts
Public ContactZhao Jianxin
Jiangnan University
Outcome results
None listed